Carlsmed (CARL) Preferred Stock Liabilities (2024 - 2025)
Carlsmed's (CARL) quarterly Preferred Stock Liabilities came in at $65.4 million in Q2 2025, up 70.5% on a YoY basis from $38.3 million in Q2 2024, and little changed quarter-over-quarter from $65.4 million in Q1 2025.
Powered by 
Analysis
Carlsmed (CARL) Preferred Stock Liabilities (2024 - 2025) Analysis & Trends
Carlsmed (CARL) has reported Preferred Stock Liabilities for 2 consecutive years, with $65.4 million the latest figure, recorded in Q2 2025.
- For the quarter ending Q2 2025, Preferred Stock Liabilities rose 70.5% year-over-year to $65.4 million; the trailing twelve-month figure through Jun 2025 stood at $65.4 million (up 70.5% YoY), and the FY2024 full-year result was $52.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities steadied at $65.4 million in Q2 2025 per CARL's latest filing, from $65.4 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $65.4 million in Q1 2025 and bottomed at $38.3 million in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.42 Bn | 182.47 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 129.78 Bn | 124.69 Bn | 1.96 Bn | - |
| 3 | Medtronic | 120.53 Bn | 112.33 Bn | 6.34 Bn | - |
| 4 | Stryker | 116.28 Bn | 112.80 Bn | 4.50 Bn | - |
| 5 | Boston Scientific | 69.29 Bn | 68.99 Bn | 3.85 Bn | - |
| 6 | Edwards Lifesciences | 51.83 Bn | 47.68 Bn | 1.35 Bn | - |
| 7 | Alcon | 34.36 Bn | 32.91 Bn | 1.68 Bn | - |
| 8 | Dexcom | 33.17 Bn | 31.23 Bn | 830.00 Mn | - |
| 9 | Resmed | 32.94 Bn | 31.47 Bn | 861.22 Mn | - |
| 10 | Carlsmed | 424.72 Mn | 311.42 Mn | 14.54 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 65.35 Mn |
| Mar 31, 2025 | 65.35 Mn |
| Dec 31, 2024 | 52.85 Mn |
| Sep 30, 2024 | 52.85 Mn |
| Jun 30, 2024 | 38.33 Mn |